DepoMed (DEPO) Misses Q1 EPS by 14c; Guides FY15 Sales Above Views

DepoMed (NASDAQ: DEPO) reported Q1 EPS of ($0.13), $0.14 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $31.7 million versus the consensus estimate of $33.8 million.

DepoMed sees FY2015 revenue of $310-335 million, versus the consensus of $305.02 million.

For earnings history and earnings-related data on DepoMed (DEPO) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• CVG to join Russell 2000 and Russell 3000 indexes June 26